BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33738970)

  • 1. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
    Klotz DM; Link T; Wimberger P; Kuhlmann JD
    Mol Oncol; 2021 Dec; 15(12):3626-3638. PubMed ID: 33738970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.
    Klotz DM; Link T; Goeckenjan M; Wimberger P; Kuhlmann JD
    Mol Oncol; 2021 Sep; 15(9):2491-2503. PubMed ID: 33690968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
    Moran-Jones K
    Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients.
    Cañadas I; Taus A; González I; Villanueva X; Gimeno J; Pijuan L; Dómine M; Sánchez-Font A; Vollmer I; Menéndez S; Arpí O; Mojal S; Rojo F; Rovira A; Albanell J; Arriola E
    Oncotarget; 2014 Jul; 5(14):5246-56. PubMed ID: 25026301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
    Link T; Passek S; Wimberger P; Frank K; Vassileva YD; Kramer M; Kuhlmann JD
    Int J Cancer; 2020 May; 146(9):2608-2618. PubMed ID: 31509615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
    Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
    Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.
    Tsuji T; Sakamori Y; Ozasa H; Yagi Y; Ajimizu H; Yasuda Y; Funazo T; Nomizo T; Yoshida H; Nagai H; Maeno K; Oguri T; Hirai T; Kim YH
    Oncotarget; 2017 Sep; 8(42):71805-71816. PubMed ID: 29069748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis.
    Klotz DM; Kuhlmann JD; Link T; Goeckenjan M; Hofbauer LC; Göbel A; Rachner TD; Wimberger P
    Front Oncol; 2022; 12():974885. PubMed ID: 36338759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy.
    Serilmez M; Özgür E; Karaman S; Gezer U; Duranyıldız D
    Cancer Biomark; 2019; 25(2):177-184. PubMed ID: 31104010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
    Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M
    Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis.
    Aune G; Lian AM; Tingulstad S; Torp SH; Forsmo S; Reseland JE; Stunes AK; Syversen U
    Gynecol Oncol; 2011 May; 121(2):402-6. PubMed ID: 21284996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Fujikawa H; Matsushita K; Okugawa Y; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Int J Oncol; 2012 Feb; 40(2):583-91. PubMed ID: 21922134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.
    Kim H; Youk J; Yang Y; Kim TY; Min A; Ham HS; Cho S; Lee KH; Keam B; Han SW; Oh DY; Ryu HS; Han W; Park IA; Kim TY; Noh DY; Im SA
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):707-14. PubMed ID: 26577828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance].
    Zhang RT; Shi HR; Huang HL; Chen ZM; Liu HN; Yuan ZF
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1551-5. PubMed ID: 21945764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts.
    Baykal C; Demirtaş E; Al A; Ayhan A; Yüce K; Tulunay G; Köse MF; Ayhan A
    Int J Gynecol Cancer; 2004; 14(1):152-6. PubMed ID: 14764044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients.
    Klotz DM; Link T; Goeckenjan M; Wimberger P; Poetsch AR; Jaschke N; Hofbauer LC; Göbel A; Rachner TD; Kuhlmann JD
    Clin Chem Lab Med; 2022 Jan; 60(1):109-117. PubMed ID: 34687595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: relationship to disease characteristics.
    Aref S; Mabed M; Sakrana M; Goda T; El-Sherbiny M
    Hematology; 2002 Oct; 7(5):273-9. PubMed ID: 12850814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Hepatocyte growth factor and its soluble receptor (s-cMet) in the serum of patients with different grades of meningioma.
    Mashayekhi F; Sasani ST; Saberi A; Salehi Z
    J Clin Neurosci; 2021 Nov; 93():1-5. PubMed ID: 34656230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.